Recently, Nakamura et al. developed an immunoprecipitation (IP) and MALDI-MS-based approach to measure plasma Aβ and proposed an AD composite biomarker based on (APP)669–711/Aβ1–42 and Aβ1–40/Aβ1–42 ratios [71]. This evidence concerns the gene APP and Alzheimer disease.